Bryan Cave is advising Zevra, and Pillsbury is advising Acer Therapeutics. Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) and Acer Therapeutics Inc. (Nasdaq: ACER) announced the companies have entered into...
Zevra Therapeutics’ $91 Million Acquisition of Acer Therapeutics
Acer Therapeutics’ $2.675 Million Registered Direct Offering
Pillsbury advised Acer Therapeutics on the deal. Acer Therapeutics, a leading pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and...